0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nabriva Therapeutics
Its shares trade under the ticker NBRVF. It has been listed since 18 September 2015. In the fiscal year to 31 December 2022, it reported revenue of $35.7m and a net loss of $57.2m. At that date it held total assets of $31.8m and shareholders' equity of $3.3m.
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Sept 2015
- Employees
- 39
- Website
- nabriva.com ↗
Leadership
Pay as last reported
- Mr. Daniel BurgessIndependent Chairman of the Board$132,594
- Mr. H. Michael HoganChief Executive Officer
- Mr. Dave MaggioChief Financial Officer
- Dr. Christine Guico-PabiaChief Medical Officer
- Dr. Steven GeloneDirector, since 2014$1.5m
- Mr. Theodore SchroederDirector, since 2018$1.2m
- Mr. Charles RowlandIndependent Director$103,481
- Mr. Stephen WebsterIndependent Director$112,002
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nabriva Therapeutics PLC has a focused portfolio with products SIVEXTRO and XENLETA for treating serious infections.
- The company has a development product candidate CONTEPO targeting Gram-negative and Gram-positive bacteria.
- Nabriva operates in the pharmaceutical sector with a specific focus on anti-infective agents.
Weaknesses
- The company has only 39 employees, indicating limited operational capacity.
- Nabriva's product portfolio is limited to two commercial products and one development candidate.
- The company's IPO was in 2015, suggesting a relatively short market history.
Opportunities
- The growing need for novel anti-infective agents against drug-resistant bacteria presents a market opportunity.
- CONTEPO's development could expand Nabriva's product offerings in the antibiotic market.
- The company's focus on anti-infective agents aligns with global health priorities for combating infections.
Threats
- Nabriva's small employee count may hinder its ability to compete in a large pharmaceutical market.
- The company's limited product portfolio increases vulnerability to market changes.
- The pharmaceutical industry faces high regulatory and development risks for new products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.